BTIG analyst Ryan Zimmerman has maintained their neutral stance on PRCT stock, giving a Hold rating on September 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Zimmerman has given his Hold rating due to a combination of factors impacting PROCEPT BioRobotics. The company’s stock has seen a significant decline, and despite the ability to exceed its own guidance, the results have not met expectations. The introduction of a new CEO presents an opportunity for change, but several challenges remain.
Utilization rates need improvement, as the current growth does not align with future guidance expectations. Additionally, the Street’s projections for FY26 sales appear optimistic, with limited room for upside unless new growth avenues are discovered. Operating expenses have also been a concern, growing at a rate that challenges the path to profitability. While the valuation is more attractive now, it aligns with industry peers, and concerns about utilization and sales persist, justifying the Hold rating.
In another report released on September 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $39.00 price target.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRCT in relation to earlier this year.